FRED HUTCHINSON CANCER CENTER

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website
https://www.fredhutch.org
prnewswire.com
·

Studies Highlight Progress in Preventing and Treating Blood Cancers and Pre-Cancerous Conditions

Studies at the 66th ASH Annual Meeting highlight progress in preventing and treating blood cancers, including daratumumab reducing disease progression risk by half in high-risk multiple myeloma patients, acalabrutinib and venetoclax combination improving progression-free survival in untreated CLL patients, epcoritamab showing promise in relapsed/refractory CLL, genetic changes and elevated leukemia risk in Ground Zero first responders, and socioeconomic factors limiting access to stem cell transplants for AML patients.
pharmacytimes.com
·

Expert Highlights Zanubrutinib's Sustained Efficacy, Favorable Safety Profile in CLL

Mazyar Shadman discusses the long-term efficacy and safety of zanubrutinib in CLL, highlighting deepening responses and no new safety signals. He compares its safety profile to traditional therapies and explains its mechanism of action contributing to high efficacy. Shadman also mentions ongoing research efforts to optimize BTKis in CLL, including combination therapies, and emphasizes the importance of clinical trials.
nature.com
·

Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale ...

K-562 cells cultured in RPMI medium with 10% FBS and 100 µg ml−1 penicillin–streptomycin. hTERT RPE-1 cells in DMEM with similar supplements. RPE-1 p53−/− from Stephen Jackson. CD34+ HSPCs for scRNA-seq in StemSpan SFEM II media. Editing experiments with CD34+ HSPCs in StemSpan SFEM II medium with growth factors. Human upper airway organoids cultured in BME droplets. FIRE reporter cell line generated by lentiviral transduction of K-562 cells. Editing reagents summarized in Supplementary Table 1. Electroporation and DNA repair inhibition detailed. Flow cytometry, gDNA extraction, amplicon sequencing, nanopore sequencing, scRNA-seq, ddPCR, Sanger sequencing, and CAST-seq methods described. Statistical analysis with GraphPad Prism 10.
targetedonc.com
·

Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer

Petros Grivas discusses unanswered questions on bladder cancer treatment, including rechallenging patients with checkpoint inhibitors after metastatic recurrence and sequencing therapies like pembrolizumab plus enfortumab vedotin. He emphasizes the need for trials in this setting and highlights the importance of germline mutation testing for early cancer detection.
fredhutch.org
·

10 years in, HICOR's efforts boost cancer care's value

VCC Summit addressed barriers to high-quality cancer care, featuring Paula Chambers Raney, a colorectal cancer patient advocate, who shared her experience of bias and delayed diagnosis. Matthew Mateo Banegas, PhD, MPH, discussed the importance of screening for financial issues in cancer patients.
fredhutch.org
·

De novo proteins to degrade unwanted proteins

The 2024 Nobel Prize in Chemistry was awarded to Dr. David Baker for computational protein design, along with Drs. Hassabis and Jumper for protein structure prediction. Baker's Rosetta software enables rapid, precise protein design, leading to applications like EndoTags, proteins enhancing endocytosis for targeted protein degradation.
fredhutch.org
·

Barriers to adherence of 1-year surveillance colonoscopy for CRC patients

CRC remains a leading cause of cancer-related deaths in the US; only 56% of CRC patients complete a 1-year surveillance colonoscopy. Researchers identified fragmented care across multiple healthcare systems as a major barrier, leading to lost follow-up reminders and notifications. Better care coordination is needed to improve surveillance among CRC survivors.
drugs.com
·

Bird Flu Virus in Canadian Teen Shows Mutations That Could Help It Spread Among Humans

Canadian teen's H5N1 bird flu virus shows mutations potentially aiding human-to-human spread, though no further cases identified. California child also tests positive for bird flu without known animal contact, raising concerns about potential human transmission.
biospace.com
·

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech announces FDA approval for Emrosi to treat rosacea and potential approval for cosibelimab for cutaneous squamous cell carcinoma, with financial results and recent corporate highlights for Q3 2024.
© Copyright 2024. All Rights Reserved by MedPath